The Maudsley Prescribing Guidelines Series-The Maudsley Deprescribing Guidelines Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs

Afbeeldingen
Artikel vergelijken
  • Engels
  • Paperback
  • 9781119822981
  • 15 februari 2024
  • 592 pagina's
Alle productspecificaties

Samenvatting

Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more.

Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so.

The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment.

This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts).

Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as:

  • Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs
  • Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process
  • Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat
  • The difference between physical dependence and addiction/substance use disorder
  • Explanation of why and how to implement hyperbolic tapering in clinical practice
  • Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches
  • Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual
  • Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse.

Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.



The Maudsley® Deprescribing Guidelines

Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more.

Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so.

The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment.

This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts).

Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as:

  • Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs
  • Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process
  • Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat
  • The difference between physical dependence and addiction/substance use disorder
  • Explanation of why and how to implement hyperbolic tapering in clinical practice
  • Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches
  • Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual
  • Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse.

Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.

Productspecificaties

Inhoud

Taal
en
Bindwijze
Paperback
Oorspronkelijke releasedatum
15 februari 2024
Aantal pagina's
592

Betrokkenen

Hoofdauteur
Mark Horowitz
Hoofduitgeverij
Wiley-Blackwell

Overige kenmerken

Product breedte
168 mm
Product hoogte
28 mm
Product lengte
241 mm
Verpakking breedte
168 mm
Verpakking hoogte
28 mm
Verpakking lengte
241 mm
Verpakkingsgewicht
1089 g

EAN

EAN
9781119822981

Je vindt dit artikel in

Taal
Engels
Boek, ebook of luisterboek?
Boek
Studieboek of algemeen
Studieboeken
Nog geen reviews
Kies gewenste uitvoering
Bindwijze : Paperback
Prijsinformatie en bestellen
De prijs van dit product is 62 euro en 99 cent.
Uiterlijk 30 juli in huis
Verkoop door bol
In winkelwagen
  • Prijs inclusief verzendkosten, verstuurd door bol
  • Ophalen bij een bol afhaalpunt mogelijk
  • 30 dagen bedenktijd en gratis retourneren
  • Dag en nacht klantenservice